Alnylam Pharmaceuticals, Inc.
ALNYAction· NasdaqGS· USD
L'essentiel à retenir
- • Dernier cours : 231,18 $US (cours différé)
- • Variation sur 1 an : -49,85 %
- • Type d'actif : Action
- • Place de cotation : NasdaqGS
- • Devise de cotation : USD
- • Clôture précédente : 246,74 $US
Informations
- Symbole
- ALNY
- Type
- Action
- Place
- NasdaqGS
- Devise
- USD
- Clôture veille
- 246,74 $US
- Variation 1 an
- -49,85 %
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
CAMBRIDGE, Mass., September 29, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of AMVUTTRA® (vutrisiran) ‘Play by Play,’ a U.S. educational initiative featuring former professional athletes living with the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) and the care teams who support them. Through personal stories and expert perspectives, ‘Play by Play’ aims to help people recognize the symptoms of ATTR-CM earl
Yahoo Finance · 29/09/2026 · lire l'article ↗
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Wall Street expects an even bigger rebound for this beaten-down biotech stock.
Yahoo Finance · 28/09/2026 · lire l'article ↗
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
Yahoo Finance · 20/09/2026 · lire l'article ↗
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a
Yahoo Finance · 18/09/2026 · lire l'article ↗
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate AdoptionDublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR The global oligonucleotide therapeutics market was valu
Yahoo Finance · 15/09/2026 · lire l'article ↗
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
Analysts think Alnylam could rebound strongly over the next 12 months.
Yahoo Finance · 15/09/2026 · lire l'article ↗
Titres et résumés fournis par les sources d'origine (flux Yahoo Finance). Cliquez pour lire l'article complet.
Questions fréquentes sur Alnylam Pharmaceuticals, Inc.
- Quel est le cours actuel de Alnylam Pharmaceuticals, Inc. ?
- Le dernier cours connu de Alnylam Pharmaceuticals, Inc. (ALNY) est de 231,18 $US (cours différé, fourni à titre informatif). Cette page est mise à jour régulièrement.
- Quelle est la performance de Alnylam Pharmaceuticals, Inc. sur un an ?
- Sur les 12 derniers mois, Alnylam Pharmaceuticals, Inc. (ALNY) affiche une variation de -49,85 %. Les performances passées ne préjugent pas des performances futures.
- Comment suivre Alnylam Pharmaceuticals, Inc. dans mon portefeuille ?
- Créez un compte gratuit sur AssetApp, ajoutez ALNY à l'un de vos portefeuilles et suivez sa valeur, vos plus-values et son actualité — aux côtés de vos autres actifs.
Actifs similaires
Alnylam Pharmaceuticals, Inc. : suivre cet actif
Alnylam Pharmaceuticals, Inc. (ALNY) est une action coté sur NasdaqGS en USD. Avec AssetApp, ajoutez ALNY à votre portefeuille pour suivre sa valeur, vos gains latents et réalisés, et l'évolution de votre patrimoine — sans dépendre de votre courtier.
Suivre ALNY gratuitement